ARBLI

Growth

losartan potassium

NDAORALSUSPENSION

Approved

Mar 2025

Lifecycle

Growth

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

[formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone…

Indications (11)

hypertension in adults older to lower blood pressure diabetic nephropathy with an elevated serum creatinine proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes a history of hypertension stroke in patients with hypertension left ventricular hypertrophy but there is evidence hypertension heart failure

Clinical Trials (5)

NCT00856271Phase 3Completed

Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

Started Aug 2004

287 enrolled

Essential Hypertension

NCT01149473Phase 1Completed

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions

Started Mar 2004

80 enrolled

Healthy

NCT00185094Phase 4Completed

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Started Feb 2004

60 enrolled

HypertensionInsulin ResistanceMetabolic Syndrome

NCT01149486Phase 1Completed

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions

Started Jan 2004

20 enrolled

Healthy

NCT00882440Phase 3Completed

A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)

Started Dec 1990

576 enrolled